Positive Clinical Study Results, New Product Launches, and Leadership Changes - Research Report on Allergan, Isis, Covidien, BD,

Positive Clinical Study Results, New Product Launches, and Leadership Changes
   - Research Report on Allergan, Isis, Covidien, BD, and DaVita HealthCare

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, June 27, 2013

NEW YORK, June 27, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting
Allergan, Inc. (NYSE: AGN), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS),
Covidien plc (NYSE: COV), Becton, Dickinson and Co. (NYSE: BDX) and DaVita
Healthcare Partners Inc. (NYSE: DVA). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Allergan, Inc. Research Report

On June 24, 2013, Allergan, Inc. (Allergan) announced that David E.I. Pyott,
Chairman of the Board and Chief Executive Officer of Allergan, and the
Company's Board of Directors, have named Douglas S. Ingram as President of
Allergan. Ingram will lead Allergan's global commercial operations, with
responsibility for the Company's broad portfolio of pharmaceutical, consumer,
and medical device products, including its leading ophthalmology products
facial aesthetics products (e.g. BOTOX and JUVÉDERM), and medical dermatology
products (e.g. ACZONE). Allergan stated that Ingram has been with the Company
for 17 years, and for the past three years, Ingram has served as the Company's
Executive Vice President and President, Europe, Africa and Middle East (EAME),
where he was responsible for Allergan's regional pharmaceutical and medical
device operations, with a focus on strategic planning, sales and marketing,
development and general management. Full Research Report on Allergan, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


ISIS Pharmaceuticals, Inc. Research Report

On June 23, 2013, ISIS Pharmaceuticals Inc. (Isis) announced data from Phase 2
study of ISIS-APOCIII in patients with high triglycerides and type 2 diabetes.
In the study, patients treated with ISIS-APOCIII experienced an 88% reduction
in apolipoprotein C-III (apoC-III), a 72% reduction in triglyceride levels, a
40% increase in high-density lipoprotein cholesterol (HDL-C), the 'good'
cholesterol, and improvements in other atherogenic lipid parameters. Further,
patients dosed with ISIS-APOCIII[Rx] showed consistent trends towards enhanced
insulin sensitivity with improvements in multiple measures of glucose control.
The Company also stated that it is evaluating ISIS-APOCIII in a separate Phase
2 study in patients with moderate to high triglycerides and expects to report
data from the study in the summer of 2013. The Full Research Report on ISIS
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:


Covidien plc Research Report

On June 20, 2013, Covidien plc (Covidien) announced that an independent study
called CLOTS 3, conducted by the University of Edinburgh, successfully
demonstrated the effectiveness of Covidien's Kendall SCD system with Vascular
Refill Detection Technology on immobile stroke patients. The study showed a
29.9% decrease in the development of proximal deep vein thrombosis (DVP) in
immobile stroke patients who received intermittent pneumatic compression (IPC)
using the Kendall SCD system with Vascular Refill Detection Technology, which
as per the Company, delivers sequential, circumferential, gradient compression
through thigh-length sleeves. Compared to the routine care group, the IPC
group showed a 14% mortality risk reduction (p = 0.042) during the first six
months after admission for stroke. The results of the CLOTS 3 trial were
presented at the European Stroke Conference and were also published in the
medical journal, The Lancet. The Full Research Report on Covidien plc -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


Becton, Dickinson and Co. Research Report

On June 24, 2013, BD Diagnostics, a segment of Becton, Dickinson and Co. (BD),
together with Diagenode SA, an international biotech company based in Belgium,
announced the European-only launch of the Diagenode Bordetella
pertussis/parapertussis real-time polymerase chain reaction (PCR) kit for use
on the BD MAX System. According to the Company, Bordetella pertussis is
responsible for 30-50 million annual cases of pertussis, or the "whooping
cough." Timely detection of the infection through the PCR is essential in
preventing the spread of disease and reducing the risk of widespread
outbreaks. BD further stated that PCR testing is ideal in enabling the prompt
differential diagnosis of pertussis from other respiratory diseases such as
atypical pneumonia, bronchitis, or respiratory viruses. Through BD's
collaborations with leading in vitro diagnostic (IVD) developers such as
Diagenode, the Company is rapidly expanding its molecular testing menu by
offering syndrome specific and clinically relevant IVD assays across a number
of disease syndromes. The Full Research Report on Becton, Dickinson and Co. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


DaVita Healthcare Partners Inc. Research Report

On June 24, 2013, DaVita, the dialysis division of DaVita HealthCare Partners
Inc. (DaVita HealthCare Partners), announced that it has selected Cureatr, the
enterprise messaging and workflow navigation solution for healthcare, to
enhance communication and care coordination for care teams at dialysis centers
across the country. The Company said that Cureatr's mobile care coordination
and reporting system will enable DaVita foster more robust clinical
information sharing, which may help reduce costly hospital admissions. Also,
it stated that this partnership allows DaVita to provide Cureatr's iPhone and
web apps to thousands of facility administrators, care managers, nurses, and
affiliated nephrologists. The Company also expects this to improve
communication between DaVita's dialysis care teams, resulting in more
efficient delivery of patient care.The Full Research Report on DaVita
Healthcare Partners Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.